Ethypharm is a leading specialty pharmaceutical company with a strong focus on Central Nervous System (CNS) diseases and conditions, as well as critical care situations. With a European foundation, Ethypharm has established itself as a prominent player in the pharmaceutical industry. In the CNS field, Ethypharm specializes in severe pain management and opioid dependency, offering innovative solutions to patients and healthcare providers.

Additionally, the company provides a wide range of high-quality injectable medicines for hospitals and emergency situations, contributing to critical care efforts. Ethypharm has proven its resilience during the COVID-19 pandemic, recognizing the vital role of its hospital injectable products in intensive care units. Furthermore, the company remains committed to mental health and addictive disorders, ensuring the uninterrupted supply of its medicines across all markets.

Supported by a diverse and experienced management team, Ethypharm fosters an entrepreneurial spirit and shared values. The company has a solid presence in key European markets such as Germany, France, Italy, the United Kingdom, and Spain, while also expanding its reach in China and other parts of the world through strategic partnerships. With impressive financial figures, including €359M in net sales and a workforce of approximately 1500 employees, Ethypharm is dedicated to making a positive impact in the pharmaceutical industry